Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AGuIX nanoparticles with stereotactic radiation for oligo brain metastases
2018-003994-80Phase 2Terminated
- Sponsor
- Centre Léon Bérard
- Start
- Jun 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AGuIX in brain metastases and cancer, sponsored by Centre Léon Bérard. Primary endpoint: Local control rate. Started Jun 2019; status: terminated.
02
Drugs
AGuIX
03
Conditions
brain metastasescancer
Beyond the preview
Go deeper on 2018-003994-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003994-80.